Clinical Trial Search

Primary: Change in the Frequency of Heartburn During the 7-day Period Prior to the 8 Week Visit (Visit 3) Compared to the Frequency of Heartburn During the 7-day Period Prior to…

Primary: Number of Participants With Adverse Events (AEs) — 184; 334 participants

Primary: Median Change in Visceral Adipose Tissue (VAT) Volume — -4.6 cm^2

Primary: Change in Abdominal Fat — 68.2; 50.0 grams

Primary: WOMAC VA 3.1 A Score (Total Pain) — -60; -58; -52; -67 mm — p=0.5263

Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants

Primary: Mortality — 42; 81 participants

Primary: Cognitive Function: Change From Baseline in Mini-mental State Examination (MMSE) Total at Week 12 Last Observation Carried Forward (LOCF) — 20.1; 19.7; 19.7; 18.2 Score…

Primary: Time to OZURDEX® Re-injection — 140.80 Days

Primary: Change From Baseline in the Children's Depression Rating Scale Revised (CDRS-R) Total Score at Week 8 — -28.43; -23.40 units on a scale — p=0.003

Primary: One-year Survival, The Percentage of Patients Who Are Alive One Year After Completing Protocol Treatment — 54 percentage of participants

Primary: Cognitive Assessment: Trail Making Test Part B — -14; 17; 4 seconds — p=0.008

Primary: Percent Change From Baseline to Month 6 in 24-hour Urine Uric Acid (uUA) Excretion — -58.6; -36.4; -12.7 percent change — p=<0.001

Primary: Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease…

Primary: Rate of Change in Composite Manual Muscle Testing (MMT) Score — 0.44; 0.39 MMT units per month — p=0.529